Long-Term Safety Profile of Tesamorelin Over 52 Weeks in HIV-Associated Lipodystrophy | RemedyX Labs Research Library

A research summary of Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation, examining long-term safety profile of tesamorelin over 52 weeks in hiv-associated lipodystrophy. Cited source and RUO context from RemedyX Labs.